Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198567
Title: | C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19 |
Author: | Camon, Ana Maria Alonso Moralejo, Rodrigo Muñoz Bellido, F. J. Cardozo Espinola, Celia Bernal-Maurandi, Javier Albiach, Laia Agüero, Daiana Marcos, Ma. Angeles Ambrosioni, Juan Bodro, Marta Chumbita, Mariana De la Mora, Lorena García Pouton, Nicole Dueñas, Gerard Hernández-Meneses, Marta Inciarte Portillo, Alexy Cuesta Chasco, Genoveva Meira, Fernanda Morata, Laura Puerta-Alcalde, Pedro Rico, Verónica Herrera, Sabina Tuset, Montse Castro, Pedro Prieto González, Sergio Almuedo Riera, Alex Muñoz, José Mensa Pueyo, Josep Sanjuan, Gemma Nicolás Arfelis, Josep Maria Del Rio, Ana Vila Estapé, Jordi García, Felipe Martínez, José Antonio Garcia Vidal, Carolina Soriano Viladomiu, Alex Hospital Clinic of Barcelona COVID-19 Research Group Miró Meda, José M. López-Soto, Alfonso |
Keywords: | Proteïnes de la sang Administració de medicaments Agents antiinflamatoris Malalts hospitalitzats COVID-19 SARS-CoV-2 Blood proteins Administration of drugs Antiinflammatory agents Hospital patients COVID-19 SARS-CoV-2 |
Issue Date: | 28-Mar-2022 |
Publisher: | Nature Publishing Group |
Abstract: | Dexamethasone and tocilizumab have been associated with reduction in mortality, however, the beneficial effect is not for all patients and the impact on viral replication is not well defined. We hypostatized that C-reactive protein (CRP) could help in the identification of patients requiring anti-inflammatory therapy. Patients admitted for > 48 h in our hospital for a confirmed or suspected infection by SARS-CoV-2 from February 2020 to February 2021 were retrospectively evaluated. The primary outcome was mortality at 30 days. Demographics and the most relevant variables related with the outcome were included. CRP was stratified by percentiles. Univariate and multivariate analysis were performed. A total of 3218 patients were included with a median (IQR) age of 66 (74-78) years and 58.9% were males. The rate of intensive care unit admission was 24.4% and the 30-day mortality rate was 11.8%. Within the first 5 days from admission, 1018 (31.7%) patients received dexamethasone and 549 tocilizumab (17.1%). The crude analysis showed a mortality reduction in patients receiving dexamethasone when CRP was > 13.75 mg/dL and > 3.5 mg/dL for those receiving tocilizumab. Multivariate analysis identified the interaction of CRP > 13.75 mg/dL with dexamethasone (OR 0.57; CI 95% 0.37-0.89, P = 0014) and CRP > 3.5 mg/dL with tocilizumab (0.65; CI95%:0.44-0.95, P = 0.029) as independent predictors of mortality. Our results suggest that dexamethasone and tocilizumab are associated with a reduction in mortality when prescribed to patients with a certain inflammatory activity assessed by C-reactive protein. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41598-022-08882-x |
It is part of: | Scientific Reports, 2022, vol. 12, num. 1, p. 5250 |
URI: | http://hdl.handle.net/2445/198567 |
Related resource: | https://doi.org/10.1038/s41598-022-08882-x |
ISSN: | 2045-2322 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
723521.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License